Research in community-acquired pneumonia: the next steps

Antoni Torres1*, Igancio Martín-Loeches2 and Rosario Menéndez2

Severe community-acquired pneumonia (SCAP) is usually defined as CAP admitted to an intensive care unit (ICU). The mortality associated with SCAP is still very high, particularly in patients needing mechanical ventilation (30%) [1]. Indeed, these patients represent an important target population for future research. In this ICM research document we focus on three major aspects of SCAP: (1) Influenza pneumonia; (2) adjunctive anti-inflammatory treatments; and (3) medium and long-term outcomes.

Influenza pneumonia: cutting-edge epidemiology in future pandemics

To determine the timing and spread of influenza, health agencies in Spain and abroad have used a sentinel surveillance system. Using high-quality data, it has been possible to establish the composition of a seasonal influenza vaccine, to track changes in circulating influenza viruses and to design an alert system for potential pandemic viruses. However, mechanisms for detecting triggers of severe influenza are still lacking. For this reason, the World Health Organization (WHO) introduced a sentinel surveillance system for hospitalized patients who met the definition of syndromic Severe Acute Respiratory Infection (SARI) [2]. While the rationale is extremely valid, the results regarding the feasibility of this concept are inconclusive. In the ICU setting the information is scarce; the Intensive Care Global Study on Severe Acute Respiratory Infection (IC-GLOSSARI), launched by the European Society of Intensive Care Medicine (ESICM), reported that SARI is very common in the ICU and is associated with high morbidity and mortality rates [3].

In recent years the information provided on pandemic preparedness has been extremely useful, although it has mainly been based on trends in the community and Primary Care settings [4]. The aim is to describe not only attack rates but also their severity; we believe that the implementation of the four “S”s concept for outbreaks (Seasonality, Sentinel critical care, Severity and geopolitical hospital Settings) would improve the detection of pandemics and would also help to determine strategies, triage, and priorities for optimizing patient care during hospital admission [5].

Particularly notable is the increase in the number of patients with influenza who are admitted to hospitals with bacterial co-infections. One might expect the high mortality associated with influenza to be due to the severity of the virus, but little is known about co-pathogenic mechanisms. In a large multicenter study our group recently found that co-infection was an independent risk factor for ICU, 28-day, and hospital mortality [6]. Biomarkers, used on a “one value-one intervention” basis, have the potential to rule out bacterial co-infections, but more complex models of analysis can be envisaged which include combinations or panels of biomarkers with biological plausibility and decision-tree analyses that will help to determine a wider range of clinical variables such as treatment failure, patient’s risk stratification and composite outcomes for clinical cure in randomized clinical trials [7]. Future research in SCAP should focus on all these aspects.

Coadjuvant treatments: will we be able to reduce acute mortality in SCAP?

SCAP-related mortality is still very high, particularly in patients with increased inflammatory response despite rapid, adequate antibiotic treatment.
1. Studies of corticosteroids in these populations suggest that their use reduces treatment failure [8], the development of ARDS, and mortality rates [9]. Due to their potential side effects, however, corticosteroids may not be cost-effective. These publications suggest that they are beneficial in patients with high systemic inflammatory response, but as they may increase mortality [10] in hospitalized patients with influenza in the presence of rhinovirus, adenovirus, RSV and metapneumovirus, their true value remains to be established. Only new RCTs or individual meta-analyses will be able to do determine their real benefit.

2. Macrolides are antibiotics with potent immunomodulatory effects. Retrospective analyses in SCAP have demonstrated that their inclusion in therapeutic regimes seems to reduce mortality [11]. However, many doubts and questions regarding the use of macrolides need to be resolved in the coming years: for instance, are they more effective than quinolones when combined with beta-lactams? And which particular SCAP target population will benefit most from macrolide treatment?

3. Immunoglobulins (Ig) have been administered in sepsis and in septic shock, but their use is controversial. Survival Sepsis Campaign guidelines [12] do not recommended Ig administration. The Cigma study [13] is a phase II study comparing 15% enriched IgM in patients with SCAP needing mechanical ventilation, with a primary end-point of ventilator-free days. The provisional results suggest a significant reduction in mortality in certain subgroups of patients. There is now a clear need for a large phase III trial in target populations with CAP: i.e., patients who are mechanically ventilated, and those with high levels of systemic inflammation or low levels of IgM.

Medium and long-term prognosis in pneumonia
After an episode of CAP, patients of all ages present an increased risk of long-term adverse events and mortality compared to the general population [14]. Short-term prognosis usually comprises the period up until 30 days and follow-up periods of 1 year of more have been reported in the literature as long-term [15]. In fact, the risk may even persist until 10 years after the episode, as has been described after sepsis; indeed, CAP is one of the main causes of sepsis. The most widely recognized causes of mortality related to medium and long-term prognosis include cardiovascular diseases, new lung infections and cancer. The potential mechanisms involved are: the direct adverse effect of microorganisms, the inflammatory host response, platelet activation and alterations of the endothelium or disruption of atheroma plaque. The study of biomarkers to monitor cardiovascular risk (both during the episode and at discharge) is becoming crucial for diagnosis, although several questions remain unanswered: for example, the identification of the best biomarker and/or panel of biomarkers, the precise factors triggered in each patient, its duration after the acute episode, and the associated risk factors [16]. All are important questions for designing interventional strategies and personalized treatments in order to curb poor prognosis. Currently, although proadrenomedullin (proADM) and other cardiovascular biomarkers have shown high prognostic power for community-acquired pneumonia (CAP) outcomes, their application in the clinical setting has been slow.

MicroRNA (miRNA) analysis has emerged as a useful tool for sepsis diagnosis and for prognosis. miRNAs are small non-coding RNAs which can act as master regulators of gene expression; they are able to modulate almost all biological processes and are essential for maintaining cellular homeostasis. Dysregulation of miRNA expression has been associated with aberrant gene expression and may lead to pathologic conditions [17]. Studies investigating immune responses and inflammatory responses from the perspective of the potential inhibition of translation or transcription of miRNA will be very welcome.

Conclusions
In conclusion, our main recommendation for SCAP research is that it should focus on reducing its short- and long-term mortality. The next steps can be summarized as follows:

- To investigate the epidemiology (risk and prognosis factors and etiology) of the four “S”s—Seasonality, Sentinel critical care, Severity and geopolitical Settings—in SCAP.
- To establish which patients with SCAP would benefit from coadjuvant anti-inflammatory or immunomodulatory treatment in order to reduce short-term mortality.
- To investigate biomarkers and phenotypes of SCAP patients with a higher risk of dying during hospital admission (short-term) and after hospital discharge.
Landscape analysis of CAP research

| Influenza Burden | 4 "S" criteria |
|------------------|----------------|
|                  | Coinfection    |
|                  | Biomarkers     |
|                  | Decision tree analysis |

| Prognosis        | Long term outcomes |
|------------------|--------------------|
|                  | Treatment failure  |
|                  | Biomarkers         |
|                  | Composite outcomes |

| Coadjuvant treatments | Steroids |
|-----------------------|----------|
|                       | Macrolides |
|                       | Immunoglobulins |

Author details
1 Pulmonology Department, Respiratory Institute, Hospital Clinic of Barcelona, Ciberes, IDiBAPS, Barcelona, Spain. 2 St James’s University Hospital, Trinity Centre for Health Sciences, HRB-Welcome Trust St James’s Hospital, Dublin, Ireland. 3 Pulmonology Service, University and Polytechnic Hospital La Fe, Ciberes, Valencia, Spain.

Acknowledgements
Supported by: SGR 2014/661, Ciber de Enfermedades Respiratorias (Ciberes CB06/06/0028), Pneumonia Corporate Research Program (CRP). Ciberes is an initiative of the Carlos III Health Institute. SGR: Catalan research group support unit.

Received: 5 December 2016  Accepted: 11 March 2017  Published online: 18 April 2017

References
1. Mongardon N, Max A, Bouglé A et al (2012) Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit Care 16(4):R155
2. Meerhoff TJ, Simaku A, Ulqinaku D et al (2015) Surveillance for severe acute respiratory infections (SARI) in hospitals in the WHO European region: an exploratory analysis of risk factors for a severe outcome in influenza-positive SARI cases. BMC Infect Dis 15:1–12
3. Sakr Y, Ferrer R, Reinhart K et al (2016) The intensive care global study on severe acute respiratory infection (IC-GLOSSARI): a multicenter, multinational, 14-day inception cohort study. Intensive Care Med 42(5):817–828
4. Martin-Lloeches L, van Someren Grieve F, Schultz MJ (2017) Bacterial pneumonia as an influenza complication. Curr Opin Infect Dis 30(2):201–207
5. Martin-Lloeches L, Soares M, Torres A (2016) Neces-SARI hy? Intensive Care Med 42(5):928–930
6. Martin-Lloeches L, Schultz MJ, Vincent J-L et al (2017) Increased incidence of co-infection in critically ill patients with influenza. Intensive Care Med 43(1):48–58
7. Rodríguez AH, Avilés-Jurado FX, Díaz E et al (2016) Procalcitonin (PCT) levels for ruling-out bacterial confection in ICU patients with influenza: a CHAID decision-tree analysis. J Infect 72(2):143–151
8. Torres A, Sibila O, Ferrer M et al (2015) Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313(7):677–686
9. Bi J, Yang J, Wang Y et al (2016) Efficacy and safety of adjunctive corticosteroids therapy for severe community-acquired pneumonia in adults: an updated systematic review and meta-analysis. PLoS One 11(11):e0165942
10. Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS (2016) Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 3:CD010406
11. Sligl WR, Asadi L, Eurditch DT, Tjosvold L, Marrie TJ, Majumdar SR (2014) Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 42(2):420–432
12. Rhodes A, Evans LE, Alhazzani W et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. doi:10.1007/s00134-017-4683-6
13. Welte T, Dellingmer RP, Ebbett H et al (2015) Concept for a study design in patients with severe community-acquired pneumonia: a randomised controlled trial with a novel IGM-enriched immunoglobulin preparation—the CIGNA study. Respir Med 109(6):758–767
14. Mortensen EM, Metersky ML (2012) Long-term mortality after pneumonia. Semin Respir Crit Care Med. 33(3):319–324
15. Eurditch DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR (2015) Ten-year mortality after community-acquired pneumonia. A prospective cohort. Am J Respir Crit Care Med 192(2):597–604
16. Menéndez R, Montull B, Reyes S et al (2016) Pneumonia presenting with organ dysfunctions: causative microorganisms, host factors and outcome. J Infect 73(3):419–426
17. Benz F, Roy S, Trautwein C, Roderburg C, Luedde T (2016) Circulating microRNAs as biomarkers for sepsis. Int J Mol Sci 17(1):78